An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Amylyx Pharmaceuticals (NASDAQ: AMLX) will have Co-CEOs Joshua Cohen and Justin Klee participate in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 3:05 p.m. ET. The conference will take place virtually, and a live webcast can be accessed on the company's investor relations website. A replay will be available for 90 days post-event. Amylyx Pharmaceuticals is dedicated to innovating treatments for the neurodegenerative community and is headquartered in Cambridge, Massachusetts.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, November 29, 2022 at 3:05 p.m. ET.
A live webcast of the fireside chat can be accessed under “Events” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.